At the recently concluded Precision Medicine World Conference (PMWC 2023) (January 25-27), Cindy Perettie, Head of Molecular Labs, Roche Diagnostics, led a panel discussing “Liquid Biopsy in Clinical Trials: Learnings and COVID Experiences.” Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalized healthcare. With a focus on oncology, the company believes blood-based screening will save millions of lives in the future. In order to bring better healthcare outcomes for patients, Roche is committed to investigating new cancer-screening approaches that identify more cancers earlier. Below are key points of the liquid biopsy panel discussion as communicated to BioQuick News by Ms. Perettie and Robert Loberg, PhD, VP, Oncology & Genetics, also at Roche.
Key Points of Panel Discussion
- Trends were heading upward for liquid biopsy pre-pandemic and COVID just accelerated the trend for non-invasive liquid-based testing due to ease of use and access. The same trends increased for e-consent and remote monitoring. The panel anticipated that these trends will continue.